HER2-positive Breast Cancer Clinical Trial
Official title:
Phase I/II Study of Adoptive T Cell Therapy Following In Vivo Priming With a HER-2/Neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine in Patients With Advanced Stage HER2 Overexpressing Breast Cancer
This phase I/II trial is studying the side effects of escalating doses of adoptive T cell therapy in treating patients with stage IV breast cancer. Vaccines are given to patient prior the expansion of a person's white blood cells may help the body build an effective immune response to kill tumor cells that overexpress human epidermal growth factor receptor 2 (HER2)
PRIMARY OBJECTIVES:
I. To evaluate the safety of infusing escalating doses of HER2 specific T cells into
patients with advanced HER2+ breast cancer using ex vivo expanded autologous T cells.
SECONDARY OBJECTIVES:
I. To investigate to what extent HER2 specific T cell immunity can be boosted or generated
in individuals after infusion of HER2 specific T cells.
II. To evaluate how long T cell immune augmentation persists in vivo after adoptive transfer
of HER2 specific T cells and subsequent booster immunizations.
III. To determine the development of cluster of differentiation (CD)4+ and CD8+ epitope
spreading after adoptive transfer of HER2 specific T cells.
TERTIARY OBJECTIVES:
I. To investigate the potential anti-tumor effects of HER2 specific T cells in patients with
advanced HER2+ breast cancer.
II. To determine whether indium-labeled HER-2 specific T-cells traffic to sites of
metastatic disease once adoptively transferred using SPECT or SPECT-CT imaging.
III. To assess whether adoptively transferred HER-2 specific T-cells induce acute
inflammation at metastatic sites of disease by assessing the development of tumor
inflammation after the second or third infusion of cells using PET-CT imaging.
OUTLINE: This is a phase I/II, dose-escalation study of ex vivo-expanded HER2-specific
autologous T cells.
Patients receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) intradermally
(ID) on days 1, 8, and 15. Beginning 2 weeks later, patients undergo leukapheresis to
isolate and collect peripheral blood mononuclear cells for T-cell expansion.
Patients receive cyclophosphamide intravenously (IV) once on day -1 and autologous ex
vivo-expanded HER2-specific T cell IV over 30 minutes on day 1. Treatment repeats every 7-10
days for up to three treatments. Patients receive a booster HER2/neu peptide vaccine 1 month
after the final T-cell infusion, followed by 2 additional booster vaccines at 2-month
intervals.
While on the study, patients may continue their standard-of-care (non-research) treatment
with trastuzumab and/or lapatinib IV weekly or every 3 weeks, except for 7 days before the
cyclophosphamide dose, treatment 1 and treatment 2 and at least 7 days after receiving the
second T cell vaccine. (Trastuzumab and lapatinib are not required or provided in this
study).
Before the third T cell treatment of HER2 specific T-cells we will label a small sample of
the patient's T-cells with indium-111. Prior to the final infusion of T-cells, patients will
have FDG PET-CT performed. This scan will be repeated 48 hours after T-cell infusion. In
addition, patients would then undergo SPECT or SPECT-CT imaging at 4, 24, 48, and 72 hours
(+/- 3 hours) after labeled cells have been infused.
After completion of study treatment, patients are followed up every 3 months for 1 year,
every 4 months for the following year, and then twice a year thereafter. This consists of
blood collection and contact with patients physician.
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04095390 -
A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer
|
Phase 2 | |
Recruiting |
NCT04578106 -
Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy
|
Phase 2 | |
Terminated |
NCT01912963 -
Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer
|
Phase 2 | |
Completed |
NCT01855828 -
Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
|
Phase 2 | |
Terminated |
NCT01705340 -
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
|
Phase 1 | |
Recruiting |
NCT04094896 -
TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer
|
Phase 2 | |
Recruiting |
NCT06087120 -
Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer.
|
||
Recruiting |
NCT04899908 -
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
|
Phase 2 | |
Recruiting |
NCT05346861 -
Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab
|
Phase 3 | |
Completed |
NCT03330561 -
PRS-343 in HER2-Positive Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04997798 -
Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer
|
Phase 2 | |
Not yet recruiting |
NCT04034823 -
KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04756921 -
18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response
|
||
Completed |
NCT03140553 -
TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03094052 -
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
|
Phase 2 | |
Recruiting |
NCT05511844 -
Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05325632 -
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
|
Phase 2 | |
Recruiting |
NCT05710666 -
Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)
|
Phase 2 | |
Recruiting |
NCT06161922 -
Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy
|
||
Not yet recruiting |
NCT05063643 -
Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude
|